Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 as first-line treatment in gastric cancer with severe peritoneal metastasis
jRCTs041180007Phase 2Completed
- Sponsor
- West Japan Oncology Group
- Start
- Nov 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and levoleucovorin in gastric adenocarcinoma, sponsored by West Japan Oncology Group. Primary endpoint: Overall survival. Started Nov 2018; status: completed.
02
Drugs
oxaliplatinfluorouracillevoleucovorin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs041180007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180007.